boric acidWhat was measured
Measured, with no finding
530 endpoints
Show what was measuredHide what was measured
spontaneous abortion rate
no effect
the rates related to spontaneous abortions and stillbirths from high B exposure vs low B exposure subpopulations revealed no differences of significance
PMID 10050933 · one of two readings recorded this
stillbirth rate
no effect
the rates related to spontaneous abortions and stillbirths from high B exposure vs low B exposure subpopulations revealed no differences of significance
PMID 10050933 · one of two readings recorded this
positive culture results during treatment
no effect
During the treatment, the positive culture results (15.1% vs 12.1%) and the signs and symptoms (33.3% vs. 24.2%) were similar within the 2 groups, with no significant statistical difference
PMID 11262459 · one of two readings recorded this
positive culture results during treatment
no effect
During the treatment, the positive culture results (15.1% vs 12.1%) and the signs and symptoms (33.3% vs. 24.2%) were similar within the 2 groups, with no significant statistical difference
PMID 11262459 · one of two readings recorded this
relapse after withdrawal of therapy
With the withdrawal, after 6 months relapses were common in the 2 groups (54.5%)
PMID 11262459 · one of two readings recorded this
relapse after withdrawal of therapy
With the withdrawal, after 6 months relapses were common in the 2 groups (54.5%)
PMID 11262459 · one of two readings recorded this
signs and symptoms during treatment
no effect
During the treatment, the positive culture results (15.1% vs 12.1%) and the signs and symptoms (33.3% vs. 24.2%) were similar within the 2 groups, with no significant statistical difference
PMID 11262459 · one of two readings recorded this
signs and symptoms during treatment
no effect
During the treatment, the positive culture results (15.1% vs 12.1%) and the signs and symptoms (33.3% vs. 24.2%) were similar within the 2 groups, with no significant statistical difference
PMID 11262459 · one of two readings recorded this
blood lipid profile
no effect
There was no significant effect of acute boron supplementation on plasma insulin and glucose concentration or on blood lipid or coagulation factor profile
PMID 12428176 · one of two readings recorded this
coagulation factor profile
no effect
There was no significant effect of acute boron supplementation on plasma insulin and glucose concentration or on blood lipid or coagulation factor profile
PMID 12428176 · one of two readings recorded this
factor VIIa activity after a high-fat meal
no effect
Results from this study suggest that acute boron supplementation (at 11.6 mg boron) does not alter the activity of factor VIIa following consumption of a high-fat meal
PMID 12428176 · one of two readings recorded this
factor VIIa after the high fat meal
increases, p = 0.001
Factor VIIa rose significantly following consumption of the high fat meal (1.05+/-0.07 vs 1.26+/-0.07; P< or =0.001)
PMID 12428176 · one of two readings recorded this
plasma boron concentration
increases, p = 0.001
Plasma boron concentrations were significantly higher following consumption of the boron supplement compared with placebo (0.124+/-0.02 vs 0.008+/-0.01 mg/l; P< or =0.001)
PMID 12428176 · one of two readings recorded this
plasma glucose concentration
no effect
There was no significant effect of acute boron supplementation on plasma insulin and glucose concentration or on blood lipid or coagulation factor profile
PMID 12428176 · one of two readings recorded this
plasma insulin concentration
no effect
There was no significant effect of acute boron supplementation on plasma insulin and glucose concentration or on blood lipid or coagulation factor profile
PMID 12428176 · one of two readings recorded this
postprandial plasma activated factor VII (VIIa) after a high-fat meal, with boron supplementation versus placebo in a crossover
no effect
Not recorded as a finding: this platform holds no node for the endpoint
Factor VIIa rose significantly following consumption of the high fat meal (1.05+/-0.07 vs 1.26+/-0.07; P< or =0.001), but this increase was not altered by boron supplementation.
PMID 12428176 · one of two readings recorded this
postprandial plasma insulin, glucose and blood lipids at 1, 2, 4 and 6 h after a high-fat meal; activated factor VIIa and coagulation factors VII, IX, X; dosed as 11.6 mg boron given as 102.6 mg sodium tetraborate decahydrate (Methods as summarised in abstract), crossover versus placebo
no effect, n = 15
Not recorded as a finding: a node exists but the paper states a different instrument or population
There was no significant effect of acute boron supplementation on plasma insulin and glucose concentration or on blood lipid or coagulation factor profile.
PMID 12428176 · one of two readings recorded this
association between cultured fungal species and clinical parameters
no effect
There was no significant association between the fungal species cultured and the clinical parameters did not vary with the presence or absence of different bacteria
PMID 12572722 · one of two readings recorded this
cause of relapse (bacterial versus fungal)
In four cases the infection was due to bacteria and the remaining seven were due to fungi
PMID 12572722 · one of two readings recorded this
clinical and mycological cure rates of otomycosis, ciclopiroxolamine cream or solution versus boric acid, one week of treatment with daily suction aspiration
no effect
Not recorded as a finding: the comparison was against another active treatment
In terms of clinical and mycological effectiveness, there were no significant differences between the three treatment groups, although group A (ciclopiroxolamine cream 1%) and B (ciclopiroxolamine solution 1%) both showed significantly better tolerance (Fisher's test, P < 0.05) when compared with boric acid (group C).
PMID 12572722 · one of two readings recorded this
clinical and mycological effectiveness
no effect
In terms of clinical and mycological effectiveness, there were no significant differences between the three treatment groups
PMID 12572722 · one of two readings recorded this
clinical cure rate, two weeks after the end of therapy
Two weeks after the end of therapy the clinical cure rates were 60% (group A), 65% (group B) and 80% (group C)
PMID 12572722 · one of two readings recorded this
clinical cure rate, two weeks after the end of therapy
Two weeks after the end of therapy the clinical cure rates were 60% (group A), 65% (group B) and 80% (group C)
PMID 12572722 · one of two readings recorded this
clinical cure rate, two weeks after the end of therapy
Two weeks after the end of therapy the clinical cure rates were 60% (group A), 65% (group B) and 80% (group C)
PMID 12572722 · one of two readings recorded this
clinical total cure rate, 3 days after the end of therapy
Clinical total cure rates 3 days after the end of therapy ranged from 50% in group A, 25% in group B to 22.5% in group C
PMID 12572722 · one of two readings recorded this
clinical total cure rate, 3 days after the end of therapy
Clinical total cure rates 3 days after the end of therapy ranged from 50% in group A, 25% in group B to 22.5% in group C
PMID 12572722 · one of two readings recorded this
clinical total cure rate, 3 days after the end of therapy
Clinical total cure rates 3 days after the end of therapy ranged from 50% in group A, 25% in group B to 22.5% in group C
PMID 12572722 · one of two readings recorded this
ears with completely sterile bacterial cultures before therapy
p = 0.01
Before therapy, a significant number of ears had completely sterile bacterial cultures (p < 0.01, chi2 test)
PMID 12572722 · one of two readings recorded this
Gram-negative bacteria after treatment
decreases
saprophytic Gram-positive bacteria increased after treatment, whilst Gram-negative bacteria, Pseudomonas aeruginosa and Proteus species, decreased after treatment
PMID 12572722 · one of two readings recorded this
mycological cure rate, two weeks after the end of therapy
the mycological cure rates was 65% for group A and 75% for both group B and C
PMID 12572722 · one of two readings recorded this
mycological cure rate, two weeks after the end of therapy
the mycological cure rates was 65% for group A and 75% for both group B and C
PMID 12572722 · one of two readings recorded this
mycological cure rate, two weeks after the end of therapy
the mycological cure rates was 65% for group A and 75% for both group B and C
PMID 12572722 · one of two readings recorded this
mycological cure rate
Mycological cure rates were 80% (group A), 95% (group B) and 72.5% (group C)
PMID 12572722 · one of two readings recorded this
mycological cure rate
Mycological cure rates were 80% (group A), 95% (group B) and 72.5% (group C)
PMID 12572722 · one of two readings recorded this
mycological cure rate
Mycological cure rates were 80% (group A), 95% (group B) and 72.5% (group C)
PMID 12572722 · one of two readings recorded this
presence of pus in fungal otitis externa
decreases, p = 0.001
pus was never present in fungal otitis externa (Fisher's test, P < 0.001)
PMID 12572722 · one of two readings recorded this
Proteus species after treatment
decreases
saprophytic Gram-positive bacteria increased after treatment, whilst Gram-negative bacteria, Pseudomonas aeruginosa and Proteus species, decreased after treatment
PMID 12572722 · one of two readings recorded this
Pseudomonas aeruginosa after treatment
decreases
saprophytic Gram-positive bacteria increased after treatment, whilst Gram-negative bacteria, Pseudomonas aeruginosa and Proteus species, decreased after treatment
PMID 12572722 · one of two readings recorded this
relapse rate association with predisposing conditions
no effect
In this short-term assessment the relapse rate was not significantly associated with predisposing conditions
PMID 12572722 · one of two readings recorded this
relapse with otitis externa
Eleven patients relapsed with otitis externa: four (20%) in groups A and C and three (15%) in group B
PMID 12572722 · one of two readings recorded this
relapse with otitis externa
Eleven patients relapsed with otitis externa: four (20%) in groups A and C and three (15%) in group B
PMID 12572722 · one of two readings recorded this
relapse with otitis externa
Eleven patients relapsed with otitis externa: four (20%) in groups A and C and three (15%) in group B
PMID 12572722 · one of two readings recorded this
relapse with the same fungal species as at the start
Six sites relapsed with the same fungal species as that isolated at the start of the study
PMID 12572722 · one of two readings recorded this
saprophytic Gram-positive bacteria after treatment
increases
saprophytic Gram-positive bacteria increased after treatment, whilst Gram-negative bacteria, Pseudomonas aeruginosa and Proteus species, decreased after treatment
PMID 12572722 · one of two readings recorded this
tolerance, ciclopiroxolamine groups versus boric acid
increases, p = 0.05
group A (ciclopiroxolamine cream 1%) and B (ciclopiroxolamine solution 1%) both showed significantly better tolerance (Fisher's test, P < 0.05) when compared with boric acid (group C)
PMID 12572722 · one of two readings recorded this
tolerance
The tolerance was excellent in group A
PMID 12572722 · one of two readings recorded this
prostate cancer risk
decreases, p = 0.0525
The adjusted odds ratio was 0.46 (95% confidence interval: 0.21-0.98) for the highest quartile of boron intake comparing to the lowest quartile (P for trend = 0.0525)
PMID 15010890 · one of two readings recorded this
prostate cancer risk
decreases
The adjusted odds ratio was 0.46 (95% confidence interval: 0.21-0.98) for the highest quartile of boron intake comparing to the lowest quartile (P for trend = 0.0525)
PMID 15010890 · one of two readings recorded this
baseline mean age, BMI, HbA1c and Candida species frequency
no effect
The mean age, BMI, HBA1c and frequency of various Candida species isolated at initial diagnosis were comparable in the fluconazole and boric acid treatment groups
PMID 17692922 · one of two readings recorded this
Candida species at relapse
no effect
Most of the patients relapsed with no change in Candida species
PMID 17692922 · one of two readings recorded this
HbA1c
no effect, p = 0.83, n = 40
The demographic profile and mean HbA1c (8.6+/-2.2 versus 8.8+/-2.4%, P=0.83) were comparable in patients with (n=27) and without mycological cure (n=13)
PMID 17692922 · one of two readings recorded this
mycological cure (negative high vaginal swab fungal culture) at 3 months after boric acid suppositories versus single-dose fluconazole in diabetic women with vulvovaginal candidiasis, among women already cured at day 15
12 of 19 (63.1%) boric acid versus 15 of 21 (71.4%) fluconazole remained cured, p = 0.83, n = 40
Not recorded as a finding: the comparison was against another active treatment
Fifteen of 21 (71.4%) and 12 of 19 (63.1%) women who achieved mycological cure at 15 day remain cured at three months in the fluconazole and boric acid treated groups, respectively (P=0.83).
PMID 17692922 · one of two readings recorded this
mycological cure rate at day 15 (previous study)
increases
In our previous study we had shown that patients with diabetes mellitus and VVC show an overall superior mycological cure rate (74% versus 51%) with boric acid therapy at 15th day as compared to fluconazole
PMID 17692922 · one of two readings recorded this
mycological cure retained at follow-up (women cured at day 15 who remained cured)
no effect, p = 0.83, n = 40
Fifteen of 21 (71.4%) and 12 of 19 (63.1%) women who achieved mycological cure at 15 day remain cured at three months in the fluconazole and boric acid treated groups, respectively (P=0.83)
PMID 17692922 · one of two readings recorded this
projected overall mycological cure at 3 months after 14 days of boric acid
unclear
With 74% mycological cure at 15th day, this would indicate that on an average only 46.6% of diabetic women with VVC would remain cured at 3 months after a course of 14 days boric acid therapy
PMID 17692922 · one of two readings recorded this
prostate cancer risk
no effect
Dietary boron intake and total boron intake from diet plus multivitamins were not associated with prostate cancer risk
PMID 17851770 · one of two readings recorded this
prostate cancer risk
no effect
none of the foods high in boron content was associated with a decreased risk of prostate cancer
PMID 17851770 · one of two readings recorded this
prostate cancer risk
no effect
The hazard ratio of prostate cancer for those in the highest versus lowest quartile of total boron intake was 1.17 (95% CI 0.85, 1.61)
PMID 17851770 · one of two readings recorded this
prostate cancer risk
no effect
This risk did not vary by prostate cancer stage or Gleason score
PMID 17851770 · one of two readings recorded this
lung cancer risk, joint effect of dietary boron and HRT
increases
the odds ratio for lung cancer for low dietary boron intake and no HRT use was 2.07 (95% CI: 1.53, 2.81)
PMID 18343880 · one of two readings recorded this
lung cancer risk, trend across quartiles of dietary boron intake
increases, p = 0.0001
for all women (p(trend) < 0.0001)
PMID 18343880 · one of two readings recorded this
lung cancer risk
increases
1.95 (95% CI: 1.42, 2.68)
PMID 18343880 · one of two readings recorded this
lung cancer risk
increases
1.39 (95% confidence interval (CI): 1.02, 1.90)
PMID 18343880 · one of two readings recorded this
lung cancer risk
increases
1.64 (95% CI: 1.20, 2.24)
PMID 18343880 · one of two readings recorded this
cumulative cure of bacterial vaginosis
Cumulative cure at 12, 16, and 28 weeks from initial visit was 87%, 78%, and 65%, respectively
PMID 19704395 · one of two readings recorded this
cumulative cure of bacterial vaginosis
Cumulative cure at 12, 16, and 28 weeks from initial visit was 87%, 78%, and 65%, respectively
PMID 19704395 · one of two readings recorded this
cumulative cure of bacterial vaginosis
Cumulative cure at 12, 16, and 28 weeks from initial visit was 87%, 78%, and 65%, respectively
PMID 19704395 · one of two readings recorded this
cure of bacterial vaginosis after nitroimidazole and boric acid therapy
Cure after nitroimidazole and BA therapy ranged from 88% to 92%, 7 and 12 weeks after the initial visit, respectively
PMID 19704395 · one of two readings recorded this
cure of bacterial vaginosis after nitroimidazole and boric acid therapy
Cure after nitroimidazole and BA therapy ranged from 88% to 92%, 7 and 12 weeks after the initial visit, respectively
PMID 19704395 · one of two readings recorded this
failure rate of bacterial vaginosis treatment
A failure rate of 50% was documented by 36 weeks of follow-up
PMID 19704395 · one of two readings recorded this
Erythrocyte sedimentation rate by the Westergren method, serum CRP by immunoturbidimetry, plasma fibrinogen, and fasting lipids (triglycerides, total, HDL and LDL cholesterol) over 2 weeks of calcium fructoborate versus fructose placebo
decreases
Not recorded as a finding: the result compares a group with itself, not with a control
For group 1 (see Table 2), there were significant decreases in ESR levels over the 2-week time interval as compared with the baseline (−10.25%, p < 0.05).
PMID 21607703 · one of two readings recorded this
gingival index
decreases, p = 0.05
GI and PI scores were significantly lower in the B and CHX groups compared with the C group at all time points after treatment (P <0.05)
PMID 23121460 · one of two readings recorded this
all clinical parameters (PI, GI, PD, CAL, BOP) versus baseline
decreases, p = 0.001
All clinical parameters showed statistically significant reduction at all time points compared to baseline in all groups (P <0.001)
PMID 23121460 · one of two readings recorded this
bleeding on probing (percentage)
decreases, p = 0.001
BOP (percentage) was significantly lower in the B group compared with the CHX and C groups in the first month after treatment (P <0.001)
PMID 23121460 · one of two readings recorded this
clinical attachment level reduction
decreases, p = 0.05
The PD and CAL reductions for moderately deep pockets (PD ≥5 and <7) were greater in the B group compared to other groups between baseline and 1 month (P <0.05)
PMID 23121460 · one of two readings recorded this
gingival index (GI), scale not named in the abstract
decreases
Not recorded as a finding: gingival-index node is bound to the Loe and Silness index and the abstract does not name it (instrument_not_stated)
GI and PI scores were significantly lower in the B and CHX groups compared with the C group at all time points after treatment (P <0.05).
PMID 23121460 · one of two readings recorded this
gingival index (GI), scored per the abstract without naming the scale
decreases, n = 45
Not recorded as a finding: node gingival-index requires the Loe and Silness scale; the abstract names only 'gingival index (GI)'; the sentence also pools the boric acid and chlorhexidine arms
GI and PI scores were significantly lower in the B and CHX groups compared with the C group at all time points after treatment (P <0.05).
PMID 23121460 · one of two readings recorded this
microbiologic parameters (Pg, Tf, Td) between groups
no effect, p = 0.05
No statistically significant differences were detected among the groups for microbiologic parameters at any time points after treatment (P >0.05)
PMID 23121460 · one of two readings recorded this
plaque index
decreases, p = 0.05
GI and PI scores were significantly lower in the B and CHX groups compared with the C group at all time points after treatment (P <0.05)
PMID 23121460 · one of two readings recorded this
Porphyromonas gingivalis amount
decreases, p = 0.05
The amounts of Pg, Tf, and Td were significantly reduced in all treatment groups after 1 month (P <0.05)
PMID 23121460 · one of two readings recorded this
probing depth reduction
no effect, p = 0.05
For deep pockets (PD ≥7), reductions were similar in the B and CHX groups (P >0.05)
PMID 23121460 · one of two readings recorded this
probing depth reduction
decreases, p = 0.05
The PD and CAL reductions for moderately deep pockets (PD ≥5 and <7) were greater in the B group compared to other groups between baseline and 1 month (P <0.05)
PMID 23121460 · one of two readings recorded this
subgingival Porphyromonas gingivalis, Tannerella forsythia and Treponema denticola amounts, real-time PCR
no effect, n = 45
Not recorded as a finding: no outcome node for subgingival bacterial load by qPCR
No statistically significant differences were detected among the groups for microbiologic parameters at any time points after treatment (P >0.05).
PMID 23121460 · one of two readings recorded this
Tannerella forsythia amount
decreases, p = 0.05
The amounts of Pg, Tf, and Td were significantly reduced in all treatment groups after 1 month (P <0.05)
PMID 23121460 · one of two readings recorded this
Treponema denticola amount
decreases, p = 0.05
The amounts of Pg, Tf, and Td were significantly reduced in all treatment groups after 1 month (P <0.05)
PMID 23121460 · one of two readings recorded this
whole-mouth clinical attachment level reduction
no effect, p = 0.05
Whole-mouth PD and CAL reduction was similar in all groups at all time points after treatment (P >0.05)
PMID 23121460 · one of two readings recorded this
whole-mouth probing depth and clinical attachment level reduction
no effect, n = 45
Not recorded as a finding: sentence names no arm or compound; also CAL reduction and node clinical-attachment-level-gain is a gain
Whole-mouth PD and CAL reduction was similar in all groups at all time points after treatment (P >0.05).
PMID 23121460 · both readings recorded this
whole-mouth probing depth reduction
no effect, p = 0.05
Whole-mouth PD and CAL reduction was similar in all groups at all time points after treatment (P >0.05)
PMID 23121460 · one of two readings recorded this
WOMAC total score (24 items, 0 to 96) and McGill Pain Questionnaire total score (0 to 78), change from baseline at Day 7 and Day 14, calcium fructoborate 110 mg twice daily versus placebo
decreases, WOMAC within-subject change 13.73 points lower on CFB than control, 95% CI -19.28 to -8.19, at Day 14
Not recorded as a finding: this platform holds no node for the endpoint
The within-subject change in mean WOMAC score over 14 days was estimated to be 13.73 points lower on CFB when compared to control (estimated effect =−13.73, P<0.0001, 95% confidence interval [CI] −19.28 to −8.19).
PMID 24940052 · one of two readings recorded this
WOMAC total score (24 items, three subscales, 0 to 96) and McGill Pain Questionnaire total score (0 to 78), mean within-subject change from baseline at Day 7 and Day 14, calcium fructoborate versus placebo
decreases, WOMAC change over 14 days 13.73 points lower on CFB than control (estimated effect -13.73, 95% CI -19.28 to -8.19)
Not recorded as a finding: this platform holds no node for the endpoint
The within-subject change in mean WOMAC score over 14 days was estimated to be 13.73 points lower on CFB when compared to control (estimated effect =−13.73, P<0.0001, 95% confidence interval [CI] −19.28 to −8.19).
PMID 24940052 · one of two readings recorded this
adverse effects reported on asking subjects at each visit
no effect, none reported at either dose
Not recorded as a finding: supplement-adverse-event-incidence node exists, but the sentence is agentless and does not name the compound or compare arms
No adverse effects were reported for either of the supplementation doses.
PMID 25433580 · one of two readings recorded this
fasting glucose and plasma homocysteine, within-group day 1 versus day 30
decreases, significantly decreased in the CFB-1 group, not significantly altered in placebo or CFB-2 groups
Not recorded as a finding: nodes exist (fasting-blood-glucose, plasma-total-homocysteine) but the only prose sentence is a within-arm change; the between-arm contrast is in a table row, not a sentence
The levels of glucose and homocysteine were significantly decreased in the CFB-1 supplementation group but were not significantly altered in the placebo or CFB-2 supplementation groups.
PMID 25433580 · one of two readings recorded this
fasting glucose, standard biochemical procedures
decreases
Not recorded as a finding: only prose sentence is a within-arm change over time, not the between-arm contrast (within_arm_only)
The levels of glucose and homocysteine were significantly decreased in the CFB-1 supplementation group but were not significantly altered in the placebo or CFB-2 supplementation groups.
PMID 25433580 · one of two readings recorded this
homocysteine, serum, assay not stated
decreases
Not recorded as a finding: only prose sentence is a within-arm change over time (within_arm_only); plasma total homocysteine node also requires matrix and assay, which the paper does not state
The levels of glucose and homocysteine were significantly decreased in the CFB-1 supplementation group but were not significantly altered in the placebo or CFB-2 supplementation groups.
PMID 25433580 · one of two readings recorded this
interleukin-1 beta, serum, assay not stated
decreases
Not recorded as a finding: no outcome node for IL-1 beta
Use of CFB-1 resulted in a significant decrease in IL-1β levels compared to placebo.
PMID 25433580 · one of two readings recorded this
monocyte chemoattractant protein-1 (MCP-1), serum, assay not stated
decreases
Not recorded as a finding: no outcome node for MCP-1
Study subjects using CFB-1 and CFB-2 (groups A and C) experienced a statistically significant reduction in the level of IL-6 and MCP-1 compared to the placebo group.
PMID 25433580 · one of two readings recorded this
serum IL-1 beta, CFB-1 versus placebo
decreases
Not recorded as a finding: no outcome node for IL-1 beta in the closed list
Use of CFB-1 resulted in a significant decrease in IL-1β levels compared to placebo.
PMID 25433580 · one of two readings recorded this
serum monocyte chemoattractant protein-1 (MCP-1), both CFB doses versus placebo
decreases, statistically significant reduction versus placebo in both groups
Not recorded as a finding: no outcome node for MCP-1 in the closed list
Study subjects using CFB-1 and CFB-2 (groups A and C) experienced a statistically significant reduction in the level of IL-6 and MCP-1 compared to the placebo group.
PMID 25433580 · one of two readings recorded this
duration of menstrual pain in hours, patient-recorded
decreases, n = 113
Not recorded as a finding: no outcome node for pain duration in hours; vas-pain covers intensity only
After the intervention, however, the severity and duration of pain were significantly lower in the case group than in the control group (P < 0.05).
PMID 25906949 · one of two readings recorded this
pain duration
no effect
The two groups had no significant differences in the severity and duration of pain at baseline
PMID 25906949 · one of two readings recorded this
pain severity
no effect
The two groups had no significant differences in the severity and duration of pain at baseline
PMID 25906949 · one of two readings recorded this
severity (visual analog scale) and duration (hours) of menstrual pain in primary dysmenorrhea, 10 mg/day boron versus placebo over two cycles
decreases
Not recorded as a finding: the supporting sentence never names the compound
After the intervention, however, the severity and duration of pain were significantly lower in the case group than in the control group (P < 0.05).
PMID 25906949 · one of two readings recorded this
absolute difference in cure rate (otomicroscopic absence of fungus)
increases, p = 0.028
The absolute difference in cure rates between 1 per cent clotrimazole solution and 3 per cent boric acid in 70 per cent alcohol was 17.9 per cent (95 per cent confidence interval, 2.3 to 33.5; p = 0.028)
PMID 27477534 · one of two readings recorded this
adverse events
no effect
Adverse events for the two agents were comparable
PMID 27477534 · one of two readings recorded this
number needed to treat
the number needed to treat was 6 (95 per cent confidence interval, 3.0 to 43.4)
PMID 27477534 · one of two readings recorded this
otomycosis cure, otomicroscopic absence of fungus one week after a single application; boric acid is the control arm against 1 per cent clotrimazole solution
absolute difference in cure rates 17.9 per cent (95 per cent CI 2.3 to 33.5), clotrimazole over boric acid, p = 0.028, n = 109
Not recorded as a finding: the comparison was against another active treatment
The absolute difference in cure rates between 1 per cent clotrimazole solution and 3 per cent boric acid in 70 per cent alcohol was 17.9 per cent (95 per cent confidence interval, 2.3 to 33.5; p = 0.028) and the number needed to treat was 6 (95 per cent confidence interval, 3.0 to 43.4).
PMID 27477534 · one of two readings recorded this
birth weight
decreases, p = 0.021
An increase in serum boron of 100μg/L in the third trimester corresponded to 0.9cm shorter and 120g lighter newborns (p=0.001 and 0.021, respectively)
PMID 27502898 · one of two readings recorded this
birth length, measured at birth (cm)
decreases, B -0.69 cm per 100 ug/L above 80 ug/L serum boron (95% CI -1.4; -0.024), p = 0.043
Not recorded as a finding: no outcome node for birth length
In multivariable-adjusted linear spline regression analysis (non-linear association), we found that serum boron concentrations above 80μg/L were inversely associated with birth length (B-0.69cm, 95% CI -1.4; -0.024, p=0.043, per 100μg/L increase in serum boron).
PMID 27502898 · one of two readings recorded this
birth length
decreases, p = 0.043
serum boron concentrations above 80μg/L were inversely associated with birth length (B-0.69cm, 95% CI -1.4; -0.024, p=0.043, per 100μg/L increase in serum boron)
PMID 27502898 · one of two readings recorded this
birth length
decreases, p = 0.001
An increase in serum boron of 100μg/L in the third trimester corresponded to 0.9cm shorter and 120g lighter newborns (p=0.001 and 0.021, respectively)
PMID 27502898 · one of two readings recorded this
birth weight and birth length of newborns, by serum boron concentration during pregnancy (ICP-MS)
decreases, 120 g lighter newborns per 100 ug/L increase in third-trimester serum boron, p = 0.021
Not recorded as a finding: every result is a subgroup, with no whole-population estimate
An increase in serum boron of 100μg/L in the third trimester corresponded to 0.9cm shorter and 120g lighter newborns (p=0.001 and 0.021, respectively).
PMID 27502898 · one of two readings recorded this
mean clinical attachment level (CAL) gain
increases
The mean PD reduction and mean CAL gain were greater in the BA group than the placebo group at 3 and 6 months
PMID 28474437 · one of two readings recorded this
mean clinical attachment level (CAL) gain
increases
The mean PD reduction and mean CAL gain were greater in the BA group than the placebo group at 3 and 6 months
PMID 28474437 · one of two readings recorded this
mean probing depth (PD) reduction
increases
The mean PD reduction and mean CAL gain were greater in the BA group than the placebo group at 3 and 6 months
PMID 28474437 · one of two readings recorded this
mean probing depth (PD) reduction
increases
The mean PD reduction and mean CAL gain were greater in the BA group than the placebo group at 3 and 6 months
PMID 28474437 · one of two readings recorded this
percentage radiographic intrabony defect depth reduction (DDR%) at 6 months; also probing depth reduction and clinical attachment level gain, stated as greater without a test result
increases, 36.97±3.47% BA vs 2.88±0.89% placebo, n = 39
Not recorded as a finding: this platform holds no node for the endpoint
A significantly greater mean percentage of radiographic DDR% was found in the BA group (36.97±3.47%) compared to the placebo group (2.88±0.89%) after 6 months.
PMID 28474437 · one of two readings recorded this
probing depth reduction, periodontal probe
increases
Not recorded as a finding: no outcome node for periodontal probing pocket depth at natural teeth; only the peri-implant node exists
The mean PD reduction and mean CAL gain were greater in the BA group than the placebo group at 3 and 6 months.
PMID 28474437 · one of two readings recorded this
radiographic defect depth reduction percentage (DDR%) at 6 months
increases, BA 36.97±3.47% versus placebo 2.88±0.89%
Not recorded as a finding: no outcome node for radiographic intrabony defect depth reduction
A significantly greater mean percentage of radiographic DDR% was found in the BA group (36.97±3.47%) compared to the placebo group (2.88±0.89%) after 6 months.
PMID 28474437 · one of two readings recorded this
radiographic defect depth reduction percentage (DDR%)
increases
A significantly greater mean percentage of radiographic DDR% was found in the BA group (36.97±3.47%) compared to the placebo group (2.88±0.89%) after 6 months
PMID 28474437 · one of two readings recorded this
clinical attachment level gain (relative vertical and horizontal) and probing depth reduction at 3 and 6 months in class II furcation defects; percentage bone fill on radiograph at 6 months
increases, bone fill 16.98%±1.03% vs 2.86%±0.92%, n = 48
Not recorded as a finding: the supporting sentence never names the compound
Furthermore, a significantly greater mean percentage of bone fill was found in group 1 (16.98%±1.03%) than in the placebo (2.86%±0.92%) at 6 months.
PMID 28631896 · one of two readings recorded this
mean percentage of bone fill
increases
a significantly greater mean percentage of bone fill was found in group 1 (16.98%±1.03%) than in the placebo (2.86%±0.92%) at 6 months
PMID 28631896 · one of two readings recorded this
mean probing depth reduction
increases
Greater mean probing depth reduction and mean relative vertical and horizontal clinical attachment level gain were shown to be greater in group 1 than in group 2 at 3 and 6 months
PMID 28631896 · one of two readings recorded this
mean probing depth reduction
increases
Greater mean probing depth reduction and mean relative vertical and horizontal clinical attachment level gain were shown to be greater in group 1 than in group 2 at 3 and 6 months
PMID 28631896 · one of two readings recorded this
mean relative horizontal clinical attachment level gain
increases
Greater mean probing depth reduction and mean relative vertical and horizontal clinical attachment level gain were shown to be greater in group 1 than in group 2 at 3 and 6 months
PMID 28631896 · one of two readings recorded this
mean relative horizontal clinical attachment level gain
increases
Greater mean probing depth reduction and mean relative vertical and horizontal clinical attachment level gain were shown to be greater in group 1 than in group 2 at 3 and 6 months
PMID 28631896 · one of two readings recorded this
mean relative vertical and horizontal clinical attachment level gain and probing depth reduction at 3 and 6 months, 0.75% boric acid gel versus placebo gel, class II furcation defects
increases
Not recorded as a finding: the supporting sentence never names the compound
Greater mean probing depth reduction and mean relative vertical and horizontal clinical attachment level gain were shown to be greater in group 1 than in group 2 at 3 and 6 months.
PMID 28631896 · one of two readings recorded this
mean relative vertical clinical attachment level gain
increases
Greater mean probing depth reduction and mean relative vertical and horizontal clinical attachment level gain were shown to be greater in group 1 than in group 2 at 3 and 6 months
PMID 28631896 · one of two readings recorded this
mean relative vertical clinical attachment level gain
increases
Greater mean probing depth reduction and mean relative vertical and horizontal clinical attachment level gain were shown to be greater in group 1 than in group 2 at 3 and 6 months
PMID 28631896 · one of two readings recorded this
ability to rise from a lying position
increases, p = 0.05
After 28 d, dogs fed the low and high doses had an improved ( < 0.05) ability to rise from a lying position compared to placebo
PMID 28727103 · one of two readings recorded this
ability to rise from a lying position
increases, p = 0.05
After 28 d, dogs fed the low and high doses had an improved ( < 0.05) ability to rise from a lying position compared to placebo
PMID 28727103 · one of two readings recorded this
ability to rise from a lying position
increases, p = 0.05
Large dogs fed the low dose also were shown to improve ( < 0.05) in their ability to rise from a lying position compared to dogs fed the placebo
PMID 28727103 · one of two readings recorded this
pain at its worst
decreases, p = 0.05
Sub-analysis of only large dogs (> 23 kg) showed that dogs fed the low dose had decreased ( < 0.05) pain severity score and pain at its worst compared to dogs fed the placebo
PMID 28727103 · one of two readings recorded this
pain severity score
decreases, p = 0.05
Sub-analysis of only large dogs (> 23 kg) showed that dogs fed the low dose had decreased ( < 0.05) pain severity score and pain at its worst compared to dogs fed the placebo
PMID 28727103 · one of two readings recorded this
soluble receptor for advanced glycation end products concentration increase
increases, p = 0.05
Dogs fed the high dose also had a greater ( = 0.05) increase in soluble receptor for advanced glycation end products concentration than dogs fed the placebo
PMID 28727103 · one of two readings recorded this
breast milk boron versus maternal serum boron
increases
Boron concentrations in breast milk (range: 46-786 µg/L) correlated strongly with those in maternal serum (range: 47-624 µg/L; rs = 0.94) 0-3 months post-partum
PMID 30654250 · one of two readings recorded this
infant body weight (g), length and head circumference at 0-3 and 3-6 months, against infant urinary boron measured by ICP-MS
decreases, B -141 g per log2 unit at 0-3 months; B -200 g at 3-6 months
Not recorded as a finding: another reason, stated per paper
In multivariable-adjusted linear regression, urinary boron (log2-transformed; range 60-9200 µg/L) in the youngest infants, but not maternal serum boron during pregnancy, was inversely associated with body weight at both 0-3 months (B: -141, 95% CI: -240; -42, p = 0.006) and 3-6 months (B: -200, 95% CI: -377; -23, p = 0.027).
PMID 30654250 · one of two readings recorded this
infant body weight
decreases, p = 0.006
body weight at both 0-3 months (B: -141, 95% CI: -240; -42, p = 0.006)
PMID 30654250 · one of two readings recorded this
infant body weight
decreases, p = 0.027
and 3-6 months (B: -200, 95% CI: -377; -23, p = 0.027)
PMID 30654250 · one of two readings recorded this
infant body weight
no effect
but not maternal serum boron during pregnancy, was inversely associated with body weight
PMID 30654250 · one of two readings recorded this
infant head circumference
decreases, p = 0.028
Infant urinary boron was also inversely associated with head circumference at 0-3 months (B: -0.39, 95% CI: -0.74; -0.04, p = 0.028)
PMID 30654250 · one of two readings recorded this
infant head circumference
unclear, p = 0.083
as well as length (B: -0.57, 95% CI: -1.1; -0.03, p = 0.040) and head circumference (B: -0.30, 95% CI: -0.64; 0.04, p = 0.083) at 3-6 months
PMID 30654250 · one of two readings recorded this
infant length
decreases, p = 0.04
as well as length (B: -0.57, 95% CI: -1.1; -0.03, p = 0.040) and head circumference (B: -0.30, 95% CI: -0.64; 0.04, p = 0.083) at 3-6 months
PMID 30654250 · one of two readings recorded this
change of mean total symptom score
unclear, p = 0.035
The change of mean total symptom score was significant with THS in combination with 3% BAA ear drops (p = .035)
PMID 32022618 · one of two readings recorded this
clinical cure rate
increases, p = 0.01
The clinical cure rate was higher (p = .01) with THS in combination with 3% BAA ear drops than with 3% BAA ear drops alone
PMID 32022618 · one of two readings recorded this
eradication
increases, p = 0.001
Resolution rates of pruritus, otorrhea, aural fullness, tinnitus and hypoacusis (p = .005, p = .004, p = .002, p = .001, p = .004, respectively) was higher with THS in combination with 3% BAA ear drops, as was eradication (p = .001)
PMID 32022618 · one of two readings recorded this
resolution of aural fullness
increases, p = 0.002
Resolution rates of pruritus, otorrhea, aural fullness, tinnitus and hypoacusis (p = .005, p = .004, p = .002, p = .001, p = .004, respectively) was higher with THS in combination with 3% BAA ear drops, as was eradication (p = .001)
PMID 32022618 · one of two readings recorded this
resolution of hypoacusis
increases, p = 0.004
Resolution rates of pruritus, otorrhea, aural fullness, tinnitus and hypoacusis (p = .005, p = .004, p = .002, p = .001, p = .004, respectively) was higher with THS in combination with 3% BAA ear drops, as was eradication (p = .001)
PMID 32022618 · one of two readings recorded this
resolution of otalgia
no effect
No differences were found in the percentage of patients reporting resolution of otalgia between patients receiving THS in combination with 3% BAA ear drops and those receiving only 3% BAA ear drops
PMID 32022618 · one of two readings recorded this
resolution of otorrhea
increases, p = 0.004
Resolution rates of pruritus, otorrhea, aural fullness, tinnitus and hypoacusis (p = .005, p = .004, p = .002, p = .001, p = .004, respectively) was higher with THS in combination with 3% BAA ear drops, as was eradication (p = .001)
PMID 32022618 · one of two readings recorded this
resolution of pruritus
increases, p = 0.005
Resolution rates of pruritus, otorrhea, aural fullness, tinnitus and hypoacusis (p = .005, p = .004, p = .002, p = .001, p = .004, respectively) was higher with THS in combination with 3% BAA ear drops, as was eradication (p = .001)
PMID 32022618 · one of two readings recorded this
resolution of tinnitus
increases, p = 0.001
Resolution rates of pruritus, otorrhea, aural fullness, tinnitus and hypoacusis (p = .005, p = .004, p = .002, p = .001, p = .004, respectively) was higher with THS in combination with 3% BAA ear drops, as was eradication (p = .001)
PMID 32022618 · one of two readings recorded this
Angiogenesis
increases
microscopically, the number of fibroblasts, collagen synthesis, and angiogenesis were significantly increased in Group 1
PMID 32662209 · one of two readings recorded this
chronic wound size reduction, epithelialization and granulation (macroscopic), fibroblast number, collagen synthesis and angiogenesis (histopathology), boric acid impregnated sponge versus silver nitrate sponge, both with NPWT
increases
Not recorded as a finding: the comparison was against another active treatment
Macroscopically, a decrease in wound size reduction, epithelialization and granulation were more prominent in the first group in which boric acid impregnated sponge was used than the second group in which silver sponge was used.
PMID 32662209 · one of two readings recorded this
Collagen synthesis
increases
microscopically, the number of fibroblasts, collagen synthesis, and angiogenesis were significantly increased in Group 1
PMID 32662209 · one of two readings recorded this
Epithelialization
increases
Macroscopically, a decrease in wound size reduction, epithelialization and granulation were more prominent in the first group in which boric acid impregnated sponge was used than the second group in which silver sponge was used
PMID 32662209 · one of two readings recorded this
Granulation
increases
Macroscopically, a decrease in wound size reduction, epithelialization and granulation were more prominent in the first group in which boric acid impregnated sponge was used than the second group in which silver sponge was used
PMID 32662209 · one of two readings recorded this
Number of fibroblasts
increases
microscopically, the number of fibroblasts, collagen synthesis, and angiogenesis were significantly increased in Group 1
PMID 32662209 · one of two readings recorded this
Wound size reduction
increases
Macroscopically, a decrease in wound size reduction, epithelialization and granulation were more prominent in the first group in which boric acid impregnated sponge was used than the second group in which silver sponge was used
PMID 32662209 · one of two readings recorded this
Clinical attachment level additional gain (pooled)
no effect, p = 0.08
a mean additional gain of 0.62 mm (95% CI: -0.07-1.32 mm, p = 0.08) was observed at 3 months
PMID 33513275 · one of two readings recorded this
Clinical attachment level additional gain (pooled)
increases, p = 0.05
a mean additional gain of 1.24 mm (95% CI: 0.89-1.58 mm, p < 0.05) at 6 months
PMID 33513275 · one of two readings recorded this
Probing pocket depth additional reduction (pooled)
no effect, p = 0.06
a mean additional reduction of 0.58 mm (95% CI: -0.03-1.19 mm, p = 0.06) was observed at 3 months
PMID 33513275 · one of two readings recorded this
Probing pocket depth additional reduction (pooled)
decreases, p = 0.05
a mean additional reduction of 1.18 mm (95% CI: 0.97-1.40 mm, p < 0.05) at 6 months
PMID 33513275 · one of two readings recorded this
probing pocket depth (PPD) reduction in mm, pooled mean difference at 3 and 6 months
decreases, additional reduction 0.58 mm at 3 months, 1.18 mm at 6 months
Not recorded as a finding: no_outcome_node: no probing pocket depth node exists in the outcome list
For PPD, a mean additional reduction of 0.58 mm (95% CI: -0.03-1.19 mm, p = 0.06) was observed at 3 months and a mean additional reduction of 1.18 mm (95% CI: 0.97-1.40 mm, p < 0.05) at 6 months, compared with placebo.
PMID 33513275 · one of two readings recorded this
probing pocket depth reduction, pooled mean difference vs placebo at 3 and 6 months
decreases, 6 months: additional reduction 1.18 mm (95% CI 0.97-1.40); 3 months: 0.58 mm (95% CI -0.03-1.19)
Not recorded as a finding: no outcome node for probing pocket depth (only clinical attachment level gain exists)
For PPD, a mean additional reduction of 0.58 mm (95% CI: -0.03-1.19 mm, p = 0.06) was observed at 3 months and a mean additional reduction of 1.18 mm (95% CI: 0.97-1.40 mm, p < 0.05) at 6 months, compared with placebo.
PMID 33513275 · one of two readings recorded this
Convenience of dressing operation (nurse opinion)
increases, p = 0.01
the nurses also believed the operation of ND was more convenient than CD (Z=-4.304, P<0.01)
PMID 34167284 · one of two readings recorded this
Cured time of sunburn
decreases, p = 0.01
the cured time of sunburns in ND Group was significantly shorter than that in CD Group (Z=-6.690, P<0.01)
PMID 34167284 · one of two readings recorded this
EASI score
no effect, p = 0.05
Before the treatment, the EASI and VAS score in those two groups showed no significantly difference (t=1.576, 1.492, P>0.05)
PMID 34167284 · one of two readings recorded this
EASI score
decreases, p = 0.01
the EASI score (2.4±0.4) points in ND Group was significantly lower than (4.6±0.7) points in CD Group (t=3.552, P<0.01)
PMID 34167284 · one of two readings recorded this
Time for nurses to operate the dressing
decreases, p = 0.01
The time for nurses operating ND was significantly shorter than that in CD (Z=-5.575, P<0.01)
PMID 34167284 · one of two readings recorded this
Treatment effect (efficacy)
increases, p = 0.01
the treatment effects of ND Group showed better than that in CD Group (Z=3.387, P<0.01)
PMID 34167284 · one of two readings recorded this
VAS score
no effect, p = 0.05
Before the treatment, the EASI and VAS score in those two groups showed no significantly difference (t=1.576, 1.492, P>0.05)
PMID 34167284 · one of two readings recorded this
VAS score
decreases, p = 0.01
the VAS score (0.51±0.12) points in ND Group was significantly lower than (0.98±0.19) points in CD Group (t=3.496, P<0.01)
PMID 34167284 · one of two readings recorded this
all-cause mortality
decreases
HR: 0.61, 95% CI: 0.43 to 0.87
PMID 34677681 · one of two readings recorded this
all-cause mortality
decreases
HR: 0.56, 95% CI: 0.41 to 0.76
PMID 34677681 · one of two readings recorded this
all-cause mortality
decreases, p = 0.001
+ age, sex, eGFR, CV history | Ref | 0.70 (0.48–1.03) | 0.068 | 0.35 (0.23–0.54) | < 0.001 | 0.51 (0.40–0.66) | < 0.001
PMID 34677681 · one of two readings recorded this
all-cause mortality
decreases, p = 0.004
+ dietary intake* | Ref | 0.77 (0.52–1.14) | 0.2 | 0.51 (0.30–0.84) | 0.009 | 0.63 (0.46–0.86) | 0.004
PMID 34677681 · one of two readings recorded this
all-cause mortality
decreases, p = 0.001
+ height and weight | Ref | 0.72 (0.49–1.06) | 0.093 | 0.41 (0.26–0.63) | < 0.001 | 0.56 (0.43–0.73) | < 0.001
PMID 34677681 · one of two readings recorded this
all-cause mortality
decreases, p = 0.001
+ LDL cholesterol, HDL cholesterol, triglycerides | Ref | 0.73 (0.50–1.08) | 0.1 | 0.43 (0.27–0.67) | < 0.001 | 0.58 (0.48–0.76) | < 0.001
PMID 34677681 · one of two readings recorded this
all-cause mortality
decreases, p = 0.001
+ smoking status, diabetes | Ref | 0.70 (0.48–1.03) | 0.068 | 0.37 (0.24–0.58) | < 0.001 | 0.53 (0.41–0.69) | < 0.001
PMID 34677681 · one of two readings recorded this
all-cause mortality
decreases, p = 0.001
Age, sex, eGFR, CV history, smoking, diabetes, height, weight | Ref | 0.72 (0.49–1.06) | 0.093 | 0.41 (0.26–0.63) | < 0.001 | 0.56 (0.43–0.73) | < 0.001
PMID 34677681 · one of two readings recorded this
all-cause mortality
decreases, p = 0.001
+ homocysteinea | Ref | 0.73 (0.50–1.08) | 0.1 | 0.42 (0.27–0.66) | < 0.001 | 0.58 (0.44–0.75) | < 0.001
PMID 34677681 · one of two readings recorded this
all-cause mortality
decreases, p = 0.001
+ hs-CRPa | Ref | 0.73 (0.50–1.08) | 0.1 | 0.41 (0.26–0.65) | < 0.001 | 0.57 (0.44–0.75) | < 0.001
PMID 34677681 · one of two readings recorded this
all-cause mortality
decreases, p = 0.001
+ vitamin B6, B12, folic acida | Ref | 0.76 (0.52–1.13) | 0.2 | 0.42 (0.27–0.66) | < 0.001 | 0.59 (0.46–0.77) | < 0.001
PMID 34677681 · one of two readings recorded this
all-cause mortality
decreases, p = 0.001
Univariable | Ref | 0.59 (0.41–0.86) | 0.006 | 0.36 (0.24–0.56) | < 0.001 | 0.55 (0.44–0.70) | < 0.001
PMID 34677681 · one of two readings recorded this
all-cause mortality
no effect, p = 0.068
+ age, sex, eGFR, CV history | Ref | 0.70 (0.48–1.03) | 0.068 | 0.35 (0.23–0.54) | < 0.001 | 0.51 (0.40–0.66) | < 0.001
PMID 34677681 · one of two readings recorded this
all-cause mortality
no effect, p = 0.2
+ dietary intake* | Ref | 0.77 (0.52–1.14) | 0.2 | 0.51 (0.30–0.84) | 0.009 | 0.63 (0.46–0.86) | 0.004
PMID 34677681 · one of two readings recorded this
all-cause mortality
no effect, p = 0.093
+ height and weight | Ref | 0.72 (0.49–1.06) | 0.093 | 0.41 (0.26–0.63) | < 0.001 | 0.56 (0.43–0.73) | < 0.001
PMID 34677681 · one of two readings recorded this
all-cause mortality
no effect, p = 0.1
+ LDL cholesterol, HDL cholesterol, triglycerides | Ref | 0.73 (0.50–1.08) | 0.1 | 0.43 (0.27–0.67) | < 0.001 | 0.58 (0.48–0.76) | < 0.001
PMID 34677681 · one of two readings recorded this
all-cause mortality
no effect, p = 0.068
+ smoking status, diabetes | Ref | 0.70 (0.48–1.03) | 0.068 | 0.37 (0.24–0.58) | < 0.001 | 0.53 (0.41–0.69) | < 0.001
PMID 34677681 · one of two readings recorded this
all-cause mortality
no effect, p = 0.093
Age, sex, eGFR, CV history, smoking, diabetes, height, weight | Ref | 0.72 (0.49–1.06) | 0.093 | 0.41 (0.26–0.63) | < 0.001 | 0.56 (0.43–0.73) | < 0.001
PMID 34677681 · one of two readings recorded this
all-cause mortality
no effect, p = 0.1
+ homocysteinea | Ref | 0.73 (0.50–1.08) | 0.1 | 0.42 (0.27–0.66) | < 0.001 | 0.58 (0.44–0.75) | < 0.001
PMID 34677681 · one of two readings recorded this
all-cause mortality
no effect, p = 0.1
+ hs-CRPa | Ref | 0.73 (0.50–1.08) | 0.1 | 0.41 (0.26–0.65) | < 0.001 | 0.57 (0.44–0.75) | < 0.001
PMID 34677681 · one of two readings recorded this
all-cause mortality
no effect, p = 0.2
+ vitamin B6, B12, folic acida | Ref | 0.76 (0.52–1.13) | 0.2 | 0.42 (0.27–0.66) | < 0.001 | 0.59 (0.46–0.77) | < 0.001
PMID 34677681 · one of two readings recorded this
all-cause mortality
decreases, p = 0.006
Univariable | Ref | 0.59 (0.41–0.86) | 0.006 | 0.36 (0.24–0.56) | < 0.001 | 0.55 (0.44–0.70) | < 0.001
PMID 34677681 · one of two readings recorded this
all-cause mortality
decreases, p = 0.001
+ age, sex, eGFR, CV history | Ref | 0.70 (0.48–1.03) | 0.068 | 0.35 (0.23–0.54) | < 0.001 | 0.51 (0.40–0.66) | < 0.001
PMID 34677681 · one of two readings recorded this
all-cause mortality
decreases, p = 0.009
+ dietary intake* | Ref | 0.77 (0.52–1.14) | 0.2 | 0.51 (0.30–0.84) | 0.009 | 0.63 (0.46–0.86) | 0.004
PMID 34677681 · one of two readings recorded this
all-cause mortality
decreases, p = 0.001
+ height and weight | Ref | 0.72 (0.49–1.06) | 0.093 | 0.41 (0.26–0.63) | < 0.001 | 0.56 (0.43–0.73) | < 0.001
PMID 34677681 · one of two readings recorded this
all-cause mortality
decreases, p = 0.001
+ LDL cholesterol, HDL cholesterol, triglycerides | Ref | 0.73 (0.50–1.08) | 0.1 | 0.43 (0.27–0.67) | < 0.001 | 0.58 (0.48–0.76) | < 0.001
PMID 34677681 · one of two readings recorded this
all-cause mortality
decreases, p = 0.001
+ smoking status, diabetes | Ref | 0.70 (0.48–1.03) | 0.068 | 0.37 (0.24–0.58) | < 0.001 | 0.53 (0.41–0.69) | < 0.001
PMID 34677681 · one of two readings recorded this
all-cause mortality
decreases, p = 0.001
Age, sex, eGFR, CV history, smoking, diabetes, height, weight | Ref | 0.72 (0.49–1.06) | 0.093 | 0.41 (0.26–0.63) | < 0.001 | 0.56 (0.43–0.73) | < 0.001
PMID 34677681 · one of two readings recorded this